Showing results (511-520 of 632) with videos related to
Sort By:
Pageof 64
International Journal of Radiation Oncology, Biology, Physics|April 16, 2003
Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and IIJeff M Michalski, Kathryn Winter, James A Purdy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 29, 2020
A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2)Stephen J Freedland, Jenifer Allen, Aubrey Jarman, et al.The Prostate|September 30, 2016
Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH DatabaseZachary S Zumsteg, Zinan Chen, Lauren E Howard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02A Pollack, M DeSilvio, L-Y Khor, et al.The Journal of Urology|December 17, 2013
Satisfaction with information used to choose prostate cancer treatmentScott M Gilbert, Martin G Sanda, Rodney L Dunn, et al.International Journal of Radiation Oncology, Biology, Physics|December 25, 2015
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233Timur Mitin, Asha George, Anthony L Zietman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02Li-Yan Khor, Kyounghwa Bae, Rebecca Paulus, et al.The New England Journal of Medicine|July 15, 2011
Radiotherapy and short-term androgen deprivation for localized prostate cancerChristopher U Jones, Daniel Hunt, David G McGowan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 TrialsJan C Buckner, Karla V Ballman, John C Michalak, et al.Radiation Oncology (London, England)|July 10, 2013
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomyWilliam C Jackson, Skyler B Johnson, Darren Li, et al.Pageof 64